Chinese Clinical Oncology
• 综述与讲座 • Previous Articles Next Articles
ZHENG Meiling,HUA Haiqing
Received:
Revised:
Online:
Published:
Contact:
Abstract:
Oxaliplatin has been approved for the treatment of advanced hepatocellular carcinoma(HCC)in China. FOLFOX4 regimen based on oxaliplatin has become one of the standard treatments for advanced HCC,which can significantly prolong the survival of patients with HCC,and also show good safety and tolerance. However,the clinical efficacy of oxaliplatin on HCC is very limited. The treatment failure is closely related to the resistance of HCC. This article reviews the progress about current researches on the resistance mechanism of oxaliplatin in the treatment of HCC,arming to help clinical and scientific researchers to understand the latest development,and to broaden their thinking in future work.
ZHENG Meiling,HUA Haiqing. Progress of resistance mechanism of oxaliplatin on hepatocellular carcinoma[J].Chinese Clinical Oncology, 2017, 22(4): 369-.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/
http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/Y2017/V22/I4/369
Cited